This content is from: Portfolio A Jim Simons Market Mystery — Solved? A secretive investment fund backed by the legendary quant displays a penchant for biotech stocks. There’s a good reason for that. By Richard Teitelbaum February 07, 2023
This content is from: Premium Healthcare Hedge Funds Shine as This Year’s Winning Strategy Managers are plowing money into oncology and genomics-oriented companies — and reaping rewards. By Michelle Celarier October 08, 2018
What Is Pharmacogenomics? The convergence of the life sciences, information technology, high-speed computation and genomics has created a unique industry that may well be among the most attractive investment opportunity for investors today. By Udayan Gupta September 13, 2010
This content is from: Portfolio How to Profit from Faster FDA and Better Science Buoyed by advances in genomics and a speedier FDA, health care investors are seeking moneymaking opportunities among pharmaceuticals companies developing expensive, new drugs. By Fran Hawthorne August 01, 2012
Why Health Care Is Looking Healthier Tony Butler, managing director and senior health care analyst at Barclays Capital, talks to Institutional Investor contributor Fran Hawthorne about investing in health care. By Fran Hawthorne September 09, 2010
Sponsored Yale Endowment Fund Amends Portfolio Yale Endowment Fund has altered its portfolio in the first quarter of 2011. May 15, 2011
